Nathaniel Fleming

Nathaniel Fleming

Auto-generated profile, based on publicly available information

Nathaniel Fleming

Department of Neurology (N.F., K.Y.), Weill Institute for Neurosciences, University of California, San Francisco

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
GCGregory A. Chang
Gregory A. Chang
JWJennifer M. Wiggins
Jennifer M. Wiggins
BCBroderick C. Corless
Broderick C. Corless
MSMahrukh M. Syeda
Mahrukh M. Syeda
JTJyothirmayee S. Tadepalli
Jyothirmayee S. Tadepalli
DPDavid Polsky
David Polsky

13 July 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NFNathaniel H Fleming
Nathaniel H Fleming
MGMadeline M Grade
Madeline M Grade
EBEran Bendavid
Eran Bendavid
Early diagnosis of cutaneous melanoma is critical in preventing melanoma-associated deaths, but the role of primary care providers (PCPs) in diagnosing melanoma is underexplored. We aimed to explore the association of PCP density with melanoma incidence and mortality. All cases of cutaneous melanoma diagnosed in the United States from 2008–2012 and reported in the Surveillance, Epidemiology, and End Results (SEER) database were analyzed in 2016. County-level primary care physician density was obtained from the Area Health Resources File (AHRF). We conducted multivariate linear regression using 1) average annual melanoma incidence or 2) average annual melanoma mortality by county as primary outcomes, adjusting for demographic confounders and dermatologist density. Cox proportional hazard regression was conducted using individual outcome data from SEER with the same covariates. Across 611 counties, 167,305 cases of melanoma were analyzed. Per 100,000 people, an additional 10 PCPs per county was associated with 1.62 additional cases of melanoma per year (95% CI 1.06–2.18, p<0.001). This increased incidence occurred disproportionally in early-stage melanoma (Stage 0: 0.69 cases (0.38–1.00), p<0.001; Stage I: 0.63 cases (0.37–0.89), p<0.001; Stage II: 0.11 cases (0.03–0.19), p = 0.005). There was no statistically significant association between PCP density and incidence of stage III or IV melanoma, or with melanoma-specific mortality. Survival analysis demonstrated elimination of 5-year post-diagnosis mortality risk in medically underserved counties after adjusting for stage. Higher densities of PCPs may be linked to increased diagnosis of early-stage melanoma without corresponding decreases in late-stage diagnoses or melanoma-associated mortality.

11 December 2023 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Open access
NFNathaniel H Fleming
Nathaniel H Fleming
ABAmber Bahorik
Amber Bahorik
FXFeng Xia
Feng Xia
KYKristine Yaffe
Kristine Yaffe
While it is widely accepted that multiple sclerosis (MS) often causes cognitive dysfunction, it is thought that these cognitive symptoms rarely progress to dementia. However, this has not been thoroughly investigated. The objectives of this cohort study are to determine whether people with MS have an increased risk of dementia compared to the general population and to identify factors, such as geographic latitude, which may modify this association. We studied data from a random sample of US veterans aged ≥ 55 years followed at Veterans Affairs Health Care Systems nationwide from 1999 to 2019. We identified all patients diagnosed with MS using ICD codes over a two-year baseline period. We then identified a comparison cohort of patients without MS matched 1:1 on sex, age, race, and first encounter date. We constructed Cox proportional hazards regression models to determine the association between MS and dementia while controlling for demographic factors and comorbidities, with additional models to examine subgroup effects. We used Fine-Gray subdistribution hazard models accounting for competing risk of death to evaluate the sensitivity of the findings. The study included 4084 MS patients and a matched group of 4084 non-MS patients. Overall, patients had mean age 66, were 93.6% male, and 88.1% non-Hispanic White, with mean follow-up time 9.5 years (MS) and 10.8 years (non-MS). In unadjusted models, veterans with MS had greater risk of dementia compared to matched controls (cumulative incidence 16.7% vs 12.4%; Cox HR 1.58, 95% CI 1.41-1.78). The increased risk remained after adjustment for potential confounders (adjusted HR 1.56, 95% CI 1.39-1.76) and when considering death as a competing risk (Fine-Gray HR 1.36, 95% CI 1.21-1.53). The magnitude of the MS-dementia association increased with rising geographic latitude (North HR 1.86, 1.51-2.30; Central HR 1.61, 1.42-1.82; South HR 1.39, 1.18-1.64; interaction p = 0.04) and younger baseline age (interaction p<0.001). Among older veterans with MS, risk of dementia diagnosis was higher compared to matched controls even after controlling for comorbidities. The risk difference was highest in northern regions and in younger patients. Clinicians caring for older MS patients should be aware of this risk and offer screening and treatment accordingly.

3 April 2023
Verified
Other
Open access
HGHeidi L. Gold
Heidi L. Gold
JWJordan Wengrod
Jordan Wengrod
EMEleazar Vega-Saenz de Miera
Eleazar Vega-Saenz de Miera
DWDing Wang
Ding Wang
NFNathaniel Fleming
Nathaniel Fleming
LGLawrence B. Gardner
Lawrence B. Gardner
PDF file - 151K, Supplemental Table 1. mutations found in NYU cohort and previously discovered by Hodis et al; and Krauthammer et al; Supplemental Table 2. Breslow-Day test of homogeneity for association between PP6C, BRAF, or NRAS mutations in Primary and Metastatic patients respectively. Supplemental Table 3. Bbaseline characteristics and prognostic factors by PP6C mutation status in primary and metastatic patients. Supplemental Table 4: PP6C, BRAF and NRAS mutation allele:wild-type allele ratios. Supplemental Table 5. Correlation of PP6R binding and Aurora A Kinase phosphorylation(primary patients only).

3 April 2023
Verified
Other
Open access
HGHeidi L. Gold
Heidi L. Gold
JWJordan Wengrod
Jordan Wengrod
EMEleazar Vega-Saenz de Miera
Eleazar Vega-Saenz de Miera
DWDing Wang
Ding Wang
NFNathaniel Fleming
Nathaniel Fleming
LGLawrence B. Gardner
Lawrence B. Gardner

18 April 2023 in Neurology
Verified
Journal Article
Closed access
PDF file
NFNathaniel H. Fleming
Nathaniel H. Fleming
LALiza Ashbrook
Liza Ashbrook